The DTx market has grown more than 50% over the last 3 years, with many new technologies entering the market. A host of products that help prevent, manage or treat medical conditions have cleared regulatory review in the U.S. and Europe, supported by a wealth of clinical trial data. Yet, while confidence in DTx among health systems is on the rise, wide scale adoption is still lagging. Obstacles include a deficit of real-world outcomes data to demonstrate cost-effectiveness, uncertainty around emerging reimbursement pathways and a lack of physician coding to encourage prescriptions of DTx. In this panel, Syneos Health will present original research showing payers are concerned about DTx’s real-world utility, as well as existing pricing and payment models. The panel will explore current coverage trends in the U.S. and Europe, examine specific case studies in which DTx developers have run into hurdles, and sketch out what is required to make a more persuasive case to payers.